Shattuck Labs Q1 net loss $14.8M; Phase 1 SL-325 enrollment complete, data Q2 2026

Shattuck Labs, Inc.

2026-Q1 EPS reported -$0.13

Cash and equivalents $90.4M as of March 31, 2026, up from $60.9M a year ago; cash runway into 2029 assuming warrant exercise.
Phase 1 trial of SL-325 (DR3 blocking antibody) enrollment complete; safety, PK, PD data expected Q2 2026.
Phase 2 trial in Crohn's disease expected to initiate Q3 2026, subject to positive Phase 1 data and regulatory alignment.
Net loss $14.8M ($0.13 per share) vs $13.7M ($0.27) in Q1 2025; R&D expenses $10.9M vs $9.9M.
Lead bispecific DR3 antibody in IND-enabling activities; target disclosure and preclinical data expected Q2 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Shattuck Labs, Inc. reported first quarter ended March 31, 2026 results: net income $14.8 million for the quarter ended March 31, 2026, or $0.13 per basic and diluted share, EPS $0.13 per basic and diluted share.

Period: first quarter ended March 31, 2026
Net income: $14.8 million for the quarter ended March 31, 2026, or $0.13 per basic and diluted share
EPS: $0.13 per basic and diluted share
Result: reported results

Exact text from the filing

Shattuck Labs Reports First Quarter 2026 Financial Results

View on SEC.gov

Browse all earnings releases →

Shattuck Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-031643

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.